NovaRx Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell-based therapeutic vaccines
for the treatment of cancer. The Company was originally founded in San Diego, California in May of 1997 by Dr. Habib Fakhrai and Mr. Emmet O'Neal III in order to commercialize
the award-winning research of Dr. Fakhrai and his associates at the Sidney Kimmel Cancer Center in San Diego and at the UCLA College of Medicine in Los Angeles.
The company's headquarters and manufacturing operations are in San Diego, California.
NovaRx's lead product candidate is Lucanix®, a whole cell-based vaccine comprised of four allogeneic cell lines. Lucanix® has successfully completed two Phase II clinical trials for the treatment of advanced stage (IIIB and IV) non-small cell lung cancer (NSCLC). NovaRX has initiated the pivotal Phase III trial. The trial is being conducted in the US, Canada, and Europe.
The proprietary core technology upon which Lucanix® is based has been exclusively licensed to NovaRx on a worldwide basis. Lucanix® is a registered trademark of NovaRx Corporation.